Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

医学 ROS1型 内科学 肺癌 腺癌 总体生存率 肿瘤科 扩展访问 胃肠病学 癌症
作者
Nikolaj Frost,Petros Christopoulos,Diego Kauffmann‐Guerrero,Jan A. Stratmann,Richard Riedel,Monica Schaefer,Jürgen Alt,S Gütz,Daniel C. Christoph,Eckart Laack,Martin Faehling,Richard Fischer,Klaus Fenchel,Sebastian P. Haen,Lukas C. Heukamp,Christian Schulz,Frank Griesinger
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:13 被引量:41
标识
DOI:10.1177/1758835920980558
摘要

We report on the results of the German early access program (EAP) with the third-generation ALK- and ROS1-inhibitor lorlatinib.Patients with documented treatment failure of all approved ALK/ROS1-specific therapies or with resistance mutations not covered by approved inhibitors or leptomeningeal carcinomatosis were enrolled and analyzed.In total, 52 patients were included [median age 57 years (range 32-81), 54% female, 62% never smokers, 98% adenocarcinoma]; 71% and 29% were ALK- and ROS1-positive, respectively. G1202R and G2032R resistance mutations prior to treatment with lorlatinib were observed in 10 of 26 evaluable patients (39%), 11 of 39 patients showed TP53 mutations (28%). Thirty-six patients (69%) had active brain metastases (BM) and nine (17%) leptomeningeal carcinomatosis when entering the EAP. Median number of prior specific TKIs was 3 (range 1-4). Median duration of treatment, progression-free survival (PFS), response rate and time to treatment failure were 10.4 months, 8.0 months, 54% and 13.0 months. Calculated 12-, 18- and 24-months survival rates were 65, 54 and 47%, overall survival since primary diagnosis (OS2) reached 79.6 months. TP53 mutations were associated with a substantially reduced PFS (3.7 versus 10.8 month, HR 3.3, p = 0.003) and were also identified as a strong prognostic biomarker (HR for OS2 3.0 p = 0.02). Neither prior treatments with second-generation TKIs nor BM had a significant influence on PFS and OS.Our data from real-life practice demonstrate the efficacy of lorlatinib in mostly heavily pretreated patients, providing a clinically meaningful option for patients with resistance mutations not covered by other targeted therapies and those with BM or leptomeningeal carcinomatosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
彭于晏的应助被狂野风华采纳,获得10
刚刚
cdercder的应助被Safe采纳,获得10
1秒前
2秒前
爱卿5271完成签到,获得积分10
2秒前
2秒前
Magic麦发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
小张爱科研完成签到 ,获得积分10
3秒前
天天快乐的应助被子木采纳,获得10
3秒前
CipherSage的应助被wwwwwwww采纳,获得10
3秒前
希望天下0贩的0的应助被123采纳,获得10
4秒前
扶风阁主完成签到,获得积分10
4秒前
三月兔发布了新的文献求助10
4秒前
4秒前
爆米花的应助被桃子采纳,获得10
4秒前
明理鸿发布了新的文献求助10
4秒前
CodeCraft的应助被红颜刹朱槿采纳,获得10
5秒前
5秒前
糊涂的中恶完成签到,获得积分10
6秒前
彭于晏发布了新的文献求助10
6秒前
洛玥发布了新的文献求助10
6秒前
7秒前
7秒前
zrf发布了新的文献求助100
8秒前
李健的粉丝团团长的应助被mjq采纳,获得10
8秒前
NexusExplorer的应助被ECCE采纳,获得10
8秒前
牧木完成签到,获得积分10
8秒前
影逐光发布了新的文献求助10
8秒前
9秒前
传奇3的应助被hahage采纳,获得50
9秒前
精明梦柏完成签到,获得积分10
9秒前
9秒前
核桃发布了新的文献求助10
9秒前
勇猛的小qin完成签到 ,获得积分10
9秒前
冷酷的问梅完成签到,获得积分10
10秒前
科研通AI2S的应助被curry采纳,获得10
10秒前
自信谷冬发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949